Cytokines, Growth Mediators and Physical Activity in Children during Puberty

Editor(s): Jürimäe, J. (Tartu)
Hills, A.P. (Brisbane, QLD)
Jürimäe, T. (Tartu)
 

Influence of Ghrelin and Adipocytokines on Bone Mineral Density in Adolescent Female Athletes with Amenorrhea and Eumenorrheic Athletes

Russell M. · Misra M.

Author affiliations

Pediatric Endocrine and Neuroendocrine Units, Massachusetts General Hospital, Boston, Mass., USA

Related Articles for ""
Jürimäe J, Hills AP, Jürimäe T (eds): Cytokines, Growth Mediators and Physical Activity in Children during Puberty. Med Sport Sci. Basel, Karger, 2010, vol 55, pp 103–113
https://doi.org/10.1159/000321975

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Complete book

  • Immediate access to all parts of this book
  • Cover-to-cover formats may be available
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restriction for personal use
read more

Pricing depends on hard-cover price

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: October 14, 2010
Cover Date: 2010

Number of Print Pages: 11
Number of Figures: 0
Number of Tables: 0

ISBN: 978-3-8055-9558-2 (Print)
eISBN: 978-3-8055-9559-9 (Online)

Abstract

Adolescent female athletes are at increased risk for low bone mineral density (BMD) secondary to exercise-induced hypogonadism. Of particular concern is that the adolescent years are also a critical time for bone accrual, and deficits incurred during this period could lead to suboptimal peak bone mass acquisition and subsequent fracture risk in later life. Although weight-bearing exercise is typically associated with an increase in BMD, amenorrheic athletes have lower BMD than eumenorrheic athletes and nonathletic controls as a consequence of low energy availability and subsequent hypogonadism. It is important to recognize that critical interactions exist between net energy availability and the hypothalamo-pituitary-gonadal (H-P-G) axis that are key to the development of a hypogonadal state when energy intake cannot keep pace with expenditure. While the link between energy availability and gonadtotropin pulsatility patterns is well established, the actual metabolic signals that link the two are less clear. Decreased energy availability in athletes is associated with decreases in fat mass, and alterations in adipokines (such as leptin and adiponectin) and fat-regulated hormones (such as ghrelin and peptide YY). These hormones impact the H-P-G axis in animal models, and it is possible that in athletes alterations in fat-related hormones signal the state of energy availability to the hypothalamus and contribute to suppression of gonadotropin pulsatility, hypothalamic amenorrhea and consequent decreased BMD. A better understanding of pathways linking low energy availability with functional hypothalamic amenorrhea and low BMD is critical for the development of future therapeutic strategies addressing these issues in amenorrheic athletes.

© 2010 S. Karger AG, Basel



Related Articles:

References

  1. Bachrach L: Acquisition of optimal bone mass in childhood and adolescence. Trends Endocrinol Metab 2001;12:22-28
  2. Christo K, Cord J, Mendes N, et al: Acylated ghrelin and leptin in adolescent athletes with amenorrhea, eumenorrheic athletes and controls: a cross-sectional study. Clin Endocrinol (Oxf) 2008;69:628-633
  3. Russell M, Stark J, Nayak S, et al: Peptide YY in adolescent athletes with amenorrhea, eumenorrheic athletes and non-athletic controls. Bone 2009;45:104-109
  4. Cobb K, Bachrach L, Greendale G, et al: Disordered eating, menstrual irregularity, and bone mineral density in female runners. Med Sci Sports Exerc 2003;35:711-719
  5. Myburgh H, Hutchins J, Fataar A, Hough S, Noakes T: Low bone mineral density is an etiologic factor for stress fractures in athletes. Ann Intern Med 1990;113:754-759
  6. Myburgh K, Bachrach L, Lewis B, Kent K, Marcus R: Low bone mineral density at axial and appendicular sites in amenorrheic athletes. Med Sci Sports Exerc 1993;25:1197-1202
  7. Pettersson U, Stalnacke B, Ahlenius G, Henriksson-Larsen K, Lorentzon R: Low bone mass density at multiple skeletal sites, including the appendicular skeleton in amenorrheic runners. Calcif Tissue Int 1999;64:117-125
  8. Loud KJ, Gordon CM, Micheli LJ, Field AE: Correlates of stress fractures among preadolescent and adolescent girls. Pediatrics 2005;115:e399-e406
  9. Christo K, Prabhakaran R, Lamparello B, et al: Bone metabolism in adolescent athletes with amenorrhea, athletes with eumenorrhea, and control subjects. Pediatrics 2008;121:1127-1136
  10. Robinson TL, Snow-Harter C, Taaffe DR, et al: Gymnasts exhibit higher bone mass than runners despite similar prevalence of amenorrhea and oligomenorrhea. J Bone Miner Res 1995;10:26-35
  11. Snow C, Rosen C, Robinson T: Serum IGF-I is higher in gymnasts than runners and predicts bone and lean mass. Med Sci Sports Exerc 2000;32:1902-1907
  12. Misra M, Prabhakaran R, Miller KK, et al: Weight gain and restoration of menses as predictors of bone mineral density change in adolescent girls with anorexia nervosa-1. J Clin Endocrinol Metab 2008;93:1231-1237
  13. Ohlsson C, Bengtsson BA, Isaksson OG, Andreassen TT, Slootweg MC: Growth hormone and bone. Endocr Rev 1998;19:55-79
  14. Rauch F: Bone accrual in children: adding substance to surfaces. Pediatrics 2007;119:(suppl 2)S137-S140
  15. Nichols JF, Rauh MJ, Lawson MJ, Ji M, Barkai HS: Prevalence of the female athlete triad syndrome among high school athletes. Arch Pediatr Adolesc Med 2006;160:137-142
  16. Drinkwater BL, Bruemner B, Chesnut CH, 3rd: Menstrual history as a determinant of current bone density in young athletes. JAMA 1990;263:545-548
  17. Jones KP, Ravnikar VA, Tulchinsky D, Schiff I: Comparison of bone density in amenorrheic women due to athletics, weight loss, and premature menopause. Obstet Gynecol 1985;66:5-8
  18. Rencken ML, Chesnut CH, 3rd, Drinkwater BL: Bone density at multiple skeletal sites in amenorrheic athletes. JAMA 1996;276:238-240
  19. Wolman RL, Clark P, McNally E, Harries M, Reeve J: Menstrual state and exercise as determinants of spinal trabecular bone density in female athletes. BMJ 1990;301:516-518
  20. Loucks AB, Verdun M, Heath EM: Low energy availability, not stress of exercise, alters LH pulsatility in exercising women. J Appl Physiol 1998;84:37-46
  21. Misra M, Prabhakaran R, Miller KK, et al: Role of cortisol in menstrual recovery in adolescent girls with anorexia nervosa. Pediatr Res 2006;59:598-603
  22. Welt CK, Chan JL, Bullen J, et al: Recombinant human leptin in women with hypothalamic amen-orrhea. N Engl J Med 2004;351:987-997
  23. Ducy P, Amling M, Takeda S, et al: Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 2000;100:197-207
  24. Hamrick MW, Pennington C, Newton D, Xie D, Isales C: Leptin deficiency produces contrasting phenotypes in bones of the limb and spine. Bone 2004;34:376-383
  25. Steppan CM, Crawford DT, Chidsey-Frink KL, Ke H, Swick AG: Leptin is a potent stimulator of bone growth in ob/ob mice. Regul Pept 2000;92:73-78
  26. Lu M, Tang Q, Olefsky JM, Mellon PL, Webster NJ: Adiponectin activates adenosine monophosphate-activated protein kinase and decreases luteinizing hormone secretion in LbetaT2 gonadotropes. Mol Endocrinol 2008;22:760-771
  27. Luo XH, Guo LJ, Xie H, et al: Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway. J Bone Miner Res 2006;21:1648-1656
  28. Luo XH, Guo LJ, Yuan LQ, et al: Adiponectin stimulates human osteoblasts proliferation and differentiation via the MAPK signaling pathway. Exp Cell Res 2005;309:99-109
  29. Rodriguez-Pacheco F, Martinez-Fuentes AJ, Tovar S, et al: Regulation of pituitary cell function by adiponectin. Endocrinology 2007;148:401-410
  30. Fukushima N, Hanada R, Teranishi H, et al: Ghrelin directly regulates bone formation. J Bone Miner Res 2005;20:790-798
  31. Kluge M, Schussler P, Uhr M, Yassouridis A, Steiger A: Ghrelin suppresses secretion of luteinizing hormone in humans. J Clin Endocrinol Metab 2007;92:3202-3205
  32. Baldock PA, Sainsbury A, Couzens M, et al: Hypothalamic Y2 receptors regulate bone formation. J Clin Invest 2002;109:915-921
  33. Fernandez-Fernandez R, Aguilar E, Tena-Sempere M, Pinilla L: Effects of polypeptide YY(3-36) upon luteinizing hormone-releasing hormone and gonadotropin secretion in prepubertal rats: in vivo and in vitro studies. Endocrinology 2005;146:1403-1410
  34. Misra M, Miller KK, Tsai P, et al: Elevated peptide YY levels in adolescent girls with anorexia nervosa. J Clin Endocrinol Metab 2006;91:1027-1033
  35. Considine RV, Sinha MK, Heiman ML, et al: Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996;334:292-295
  36. Kennedy A, Gettys TW, Watson P, et al: The metabolic significance of leptin in humans: gender-based differences in relationship to adiposity, insulin sensitivity, and energy expenditure. J Clin Endocrinol Metab 1997;82:1293-1300
  37. Saad MF, Riad-Gabriel MG, Khan A, et al: Diurnal and ultradian rhythmicity of plasma leptin: effects of gender and adiposity. J Clin Endocrinol Metab 1998;83:453-459
  38. Cambuli VM, Musiu MC, Incani M, et al: Assessment of adiponectin and leptin as biomarkers of positive metabolic outcomes after lifestyle intervention in overweight and obese children. J Clin Endo-crinol Metab 2008;93:3051-3057
  39. Yang WS, Lee WJ, Funahashi T, et al: Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 2001;86:3815-3819
  40. Misra M, Miller KK, Kuo K, et al: Secretory dynamics of leptin in adolescent girls with anorexia nervosa and healthy adolescents. Am J Physiol Endocrinol Metab 2005;289:E373-E381
  41. Farooqi IS: Leptin and the onset of puberty: insights from rodent and human genetics. Semin Reprod Med 2002;20:139-144
  42. Misra M, Miller KK, Cord J, et al: Relationships between serum adipokines, insulin levels, and bone density in girls with anorexia nervosa. J Clin Endo-crinol Metab 2007;92:2046-2052
  43. Pannacciulli N, Bunt JC, Ortega E, et al: Lower total fasting plasma adiponectin concentrations are associated with higher metabolic rates. J Clin Endocrinol Metab 2006;91:1600-1603
  44. Gimble JM, Zvonic S, Floyd ZE, Kassem M, Nuttall ME: Playing with bone and fat. J Cell Biochem 2006;98:251-266
  45. Pei L, Tontonoz P: Fat's loss is bone's gain. J Clin Invest 2004;113:805-806
  46. Jurimae J, Rembel K, Jurimae T, Rehand M: Adiponectin is associated with bone mineral density in perimenopausal women. Horm Metab Res 2005;37:297-302
  47. Lenchik L, Register TC, Hsu FC, et al: Adiponectin as a novel determinant of bone mineral density and visceral fat. Bone 2003;33:646-651
  48. Nakazato M, Murakami N, Date Y, et al: A role for ghrelin in the central regulation of feeding. Nature 2001;409:194-198
  49. Tschop M, Smiley DL, Heiman ML: Ghrelin induces adiposity in rodents. Nature 2000;407:908-913
  50. De Souza MJ, Leidy HJ, O'Donnell E, Lasley B, Williams NI: Fasting ghrelin levels in physically active women: relationship with menstrual disturbances and metabolic hormones. J Clin Endocrinol Metab 2004;89:3536-3542
  51. Jurimae J, Jurimae T, Purge P: Plasma ghrelin is altered after maximal exercise in elite male rowers. Exp Biol Med (Maywood) 2007;232:904-909
  52. Hotta M, Ohwada R, Katakami H, et al: Plasma levels of intact and degraded ghrelin and their responses to glucose infusion in anorexia nervosa. J Clin Endocrinol Metab 2004;89:5707-5712
  53. Misra M, Miller KK, Kuo K, et al: Secretory dynamics of ghrelin in adolescent girls with anorexia nervosa and healthy adolescents. Am J Physiol Endocrinol Metab 2005;289:E347-E356
  54. Vulliemoz NR, Xiao E, Xia-Zhang L, et al: Decrease in luteinizing hormone pulse frequency during a five-hour peripheral ghrelin infusion in the ovariectomized rhesus monkey. J Clin Endocrinol Metab 2004;89:5718-5723
  55. Kamegai J, Tamura H, Shimizu T, et al: Chronic central infusion of ghrelin increases hypothalamic neuropeptide Y and Agouti-related protein mRNA levels and body weight in rats. Diabetes 2001;50:2438-2443
  56. Arvat E, Maccario M, Di Vito L, et al: Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. J Clin Endocrinol Metab 2001;86:1169-1174
  57. Takaya K, Ariyasu H, Kanamoto N, et al: Ghrelin strongly stimulates growth hormone release in humans. J Clin Endocrinol Metab 2000;85:4908-4911
  58. Misra M, Miller KK, Stewart V, et al: Ghrelin and bone metabolism in adolescent girls with anorexia nervosa and healthy adolescents. J Clin Endocrinol Metab 2005;90:5082-5087
  59. Huda MS, Wilding JP, Pinkney JH: Gut peptides and the regulation of appetite. Obes Rev 2006;7:163-182
  60. Ballantyne GH: Peptide YY(1-36) and peptide YY(3-36). II. Changes after gastrointestinal surgery and bariatric surgery. Obes Surg 2006;16:795-803
  61. Keire DA, Mannon P, Kobayashi M, et al: Primary structures of PYY, [Pro(34)]PYY, and PYY-(3-36) confer different conformations and receptor selectivity. Am J Physiol Gastrointest Liver Physiol 2000;279:G126-G131
  62. Batterham RL, Cohen MA, Ellis SM, et al: Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003;349:941-948

Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: October 14, 2010
Cover Date: 2010

Number of Print Pages: 11
Number of Figures: 0
Number of Tables: 0

ISBN: 978-3-8055-9558-2 (Print)
eISBN: 978-3-8055-9559-9 (Online)

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

Table of Contents

Article

Recommend This
TOP